Eye Cancer Survival Rates: What the Numbers Mean for You
If you or someone you love has just been diagnosed with eye cancer, you may be searching for survival numbers right away. That is a normal reaction. This guide walks through what is actually known about survival for the two main types of primary eye cancer: uveal melanoma (the most common eye cancer in adults) and retinoblastoma (the most common eye cancer in children). It also explains what a "survival rate" really means, what tends to drive outcomes, and whether these cancers can be cured. As with every guide in this series, "eye cancer" here means uveal melanoma unless retinoblastoma is specifically named, since that matches how eye cancer facts are generally organized by the American Cancer Society and the National Cancer Institute.
How Common Is Eye Cancer?
Uveal melanoma, also called intraocular melanoma or ocular melanoma, is rare. It starts in the uveal tract, the middle layer of the eye that includes the choroid (the layer of blood vessels behind the retina), the ciliary body (the ring of tissue that helps focus the eye), and the iris (the colored part of the eye). Epidemiologic reviews, including a StatPearls summary of ocular melanoma and a 2020 review in Nature Reviews Disease Primers, put the incidence at roughly 5 to 6 cases per million people per year in the United States and similar populations in Europe. Even though it is rare, uveal melanoma is still the most common primary cancer of the eye in adults, meaning it is the most common cancer that actually starts inside the eye rather than spreading there from somewhere else.
Turning that rate into a yearly count is where sources start to differ, and it is worth being honest about that rather than picking one number and hiding the disagreement. The American Cancer Society estimates about 3,200 new cancers of the eye and orbit (the eye socket) in the United States each year, but that broader category includes other rare eye and orbit cancers such as lymphoma, not just uveal melanoma. When researchers apply the more disease-specific incidence rate of about 5 to 6 per million to the US population, the result is closer to 2,000 to 2,500 new uveal melanoma cases per year. Both figures are correct for what they measure. You can think of the ACS number as the ceiling for all primary eye and orbit cancers combined, and the epidemiologic rate as a tighter estimate for uveal melanoma specifically.
Uveal melanoma is diagnosed across a wide age range, but risk rises with age. Many patient resources cite an average age in the late 50s to 60s, while a StatPearls review reports a median age around 62, with the highest rates seen in people in their 70s. In practical terms, this cancer is uncommon before age 40 and becomes steadily more common with each decade after that. It affects people of all sexes, though some studies report a somewhat higher rate in men. Learn more about who tends to develop this disease and why in the guide on risk factors for eye cancer.
Retinoblastoma: a different eye cancer in young children
Retinoblastoma is a different eye cancer that mainly affects young children and works differently than uveal melanoma. It starts in the retina (the light-sensing layer at the back of the eye) and is caused by changes in the RB1 gene. Retinoblastoma is the most common eye cancer in children. In the United States, about 300 to 350 new cases are diagnosed each year, according to the American Cancer Society, accounting for roughly 3% of all childhood cancers. Two out of three cases are diagnosed before age 2, and almost all are diagnosed before age 5. About 1 in 3 children with retinoblastoma have it in both eyes (bilateral), and bilateral disease tends to show up at a younger age and is more often linked to an inherited RB1 mutation.
It is also worth knowing that eye metastases, cancer that started somewhere else in the body (most often breast cancer or lung cancer) and later spread to the eye, are actually more common than primary eye cancer of any type. The American Cancer Society notes plainly that these secondary eye cancers outnumber primary ones. Eye metastasis is not primary eye cancer. It is treated as the original cancer, with the eye as one of the places it has spread. If a doctor has found a tumor in your eye, ask directly whether it is thought to be primary (starting in the eye) or secondary (spread from elsewhere), since that changes everything about treatment and outlook. You can read more about how doctors tell these apart in the guide on how eye cancer is diagnosed.
What Is the Survival Rate for Eye Cancer?
Before looking at any numbers, it helps to understand what a "5-year relative survival rate" actually measures. It compares people with a certain type and stage of cancer to people in the general population who are similar in age but do not have that cancer. If the 5-year relative survival rate for a stage of eye cancer is 80%, that means people with that stage are, on average, about 80% as likely as people without the cancer to be alive 5 years later. This is a statistical estimate built from large groups of people diagnosed in the past. It cannot tell any one person how long they will live, and your doctor is a better source for how these numbers might apply to your specific situation.
For uveal melanoma, the American Cancer Society uses data from the National Cancer Institute's SEER program, which groups cases as localized (no spread outside the eye), regional (spread to nearby tissue or lymph nodes), or distant (spread to other organs, most often the liver). Based on people diagnosed between 2015 and 2021, the 5-year relative survival rate is 88% for localized disease, 65% for regional disease, 19% for distant disease, and 84% across all stages combined. A separate data set from Cancer Research UK, based on people diagnosed with uveal melanoma in England between 2014 and 2016, found that about 95% survived 1 year and almost 80% survived 5 years, which is a reasonably close, independent confirmation of the US figures.
Several factors beyond stage at diagnosis shape the outlook for an individual with uveal melanoma. Tumor size and location matter: larger tumors and those involving the ciliary body carry a higher risk of spreading than smaller tumors or ones confined to the iris. Genetic features of the tumor itself matter as well. Loss of one copy of chromosome 3 (called monosomy 3) and certain other chromosome changes are linked to a higher risk of metastasis, while changes in genes such as EIF1AX and SF3B1 are generally linked to a lower risk. Many centers also use gene expression profiling, such as the validated 15-gene DecisionDx-UM test, which sorts tumors into a lower-risk class or a higher-risk class for spreading. This is testing of the tumor itself (somatic testing), not necessarily something you inherited, though a small share of uveal melanoma is linked to inherited BAP1 tumor predisposition syndrome. You can read more about how these results guide monitoring in the guide on eye cancer stages.
Liver metastasis changes the picture substantially. Uveal melanoma spreads through the bloodstream rather than through lymph nodes, and when it spreads, the liver is by far the most common site. Roughly half of all people treated for uveal melanoma eventually develop metastatic disease, sometimes many years after the original eye tumor was successfully treated, which is why lifelong liver surveillance with imaging and liver function tests is a real and important recommendation, not just a formality. Historically, once uveal melanoma reached the liver, the median survival was only about 1 year, and outcomes with older chemotherapy and immunotherapy drugs were poor. That picture has genuinely improved for some patients: tebentafusp, an immunotherapy approved by the FDA for adults with HLA-A*02:01-positive metastatic uveal melanoma (a genetic marker present in about 45% of people with this cancer), was shown in a large phase 3 trial to extend median overall survival to 21.7 months, compared with 16.0 months for older standard treatments. That is a meaningful improvement, but it is honest to say that metastatic uveal melanoma remains a serious, life-limiting diagnosis for most people, and newer drugs such as darovasertib are still being studied in clinical trials for those who are not eligible for tebentafusp or whose disease progresses.
Retinoblastoma survival rates are generally excellent
Retinoblastoma survival rates are generally excellent, especially with access to good pediatric eye cancer care. In the United States, where most cases are caught while still confined to the eye, the American Cancer Society reports 5-year survival rates above 95%, and more than 9 out of 10 children with retinoblastoma in the US are cured. The outlook changes when the disease has spread beyond the eye. For retinoblastoma that has spread outside the eye but not to the brain or cerebrospinal fluid, survival ranges from about 60% to 90% depending on how far it has spread. When retinoblastoma reaches the brain or cerebrospinal fluid, survival drops sharply to well under 20%, even with intensive treatment. The single biggest factor affecting a child's outlook is how advanced the disease is at diagnosis, which is one of the strongest reasons early evaluation of a white pupil reflex (leukocoria) or unusual eye alignment (strabismus) matters so much. You can read about these warning signs in the guide on eye cancer symptoms.
Whether the numbers are for uveal melanoma or retinoblastoma, keep the same caution in mind: these statistics describe people who were diagnosed and treated in the past, often 5 or more years ago, and treatments continue to improve. They cannot predict what will happen for you or your child. Ask your own care team how your specific diagnosis, test results, and treatment plan compare with these general figures, and use the questions to ask about eye cancer guide to help prepare for that conversation.
Is Eye Cancer Curable?
For uveal melanoma, the honest answer is yes for many people, especially when the tumor is caught while it is still small and confined to the eye. Local treatment, whether plaque brachytherapy (a radioactive disc sewn temporarily onto the eye), proton beam or other radiation, or in some cases enucleation (surgical removal of the eye), controls the tumor within the eye in the large majority of patients. It helps to understand the difference between a few related but distinct terms. "Cure" generally means the cancer is gone and expected to stay gone. "Remission" means signs of cancer have decreased or disappeared, but doctors are watching closely because it could return. "No evidence of disease," often shortened to NED, means testing cannot currently find any cancer, which is reassuring but is not the same guarantee as a lifelong cure. Most people treated for uveal melanoma will be told they have no evidence of disease after successful local treatment, and for many, that status holds for the rest of their life.
Even when treatment of the eye tumor goes well, lifelong liver surveillance matters, because uveal melanoma can spread to the liver years after the original diagnosis, sometimes even a decade or more later. This is different from most cancers people have heard about, and it is a real, ongoing part of survivorship rather than a one-time concern. Your care team can set a monitoring schedule, often more frequent imaging for higher-risk tumors and less frequent imaging for lower-risk ones, based on your tumor's size, location, and genetic testing results. Details on how these tests and treatments work together are covered in the eye cancer treatment guide.
Metastatic uveal melanoma, once it has reached the liver or elsewhere, is generally not considered curable with current treatments, but it is treatable. Tebentafusp has extended survival for eligible HLA-A*02:01-positive patients, and other approaches, including liver-directed therapies and newer drugs still under study such as darovasertib, are giving some patients more time and, for a subset, meaningful disease control. Clinical trials are an important option to discuss with an ocular oncologist at this stage, since much of the recent progress in this disease has come directly from trial participation. The clinical trials guide explains how to find and evaluate trials that might fit your situation.
For retinoblastoma, the answer is also generally yes, especially with prompt treatment and access to a pediatric ophthalmology or ocular oncology center experienced in this rare cancer. Because this disease affects infants and young children, many readers of this guide are parents trying to understand what a diagnosis means for their family. It is frightening to hear "cancer" and your child's name in the same sentence, but retinoblastoma is one of the more treatable childhood cancers when caught early, and the goal of treatment is almost always to save your child's life first and, whenever medically possible, to save the eye and vision as well. Depending on how advanced the tumor is, treatment may include systemic or intra-arterial chemotherapy, focal laser treatment or cryotherapy, plaque brachytherapy, or, for advanced disease in one eye, enucleation.
Because a meaningful share of retinoblastoma is linked to an inherited RB1 mutation, genetic testing and counseling for the whole family is a real, actionable step, not an afterthought. It can identify which relatives, including future children, might need early and regular dilated eye exams starting soon after birth. If you notice a white glow in your child's pupil in photos or in person, unusual eye alignment, or any other change in how your child's eyes look or move, do not wait to have it checked. Prompt evaluation, referral to an ocular oncology or pediatric ophthalmology center, and, when appropriate, enrollment in a clinical trial are the most useful steps a family can take. Your care team, along with resources like the eye cancer support guide, can help you and your family through the process.